Companies often purchase competitors, not to acquire their ideas and products, but to shut them down. A recent report raised questions about whether such an acquisition may be partially responsible for a shortage of ventilators in the United States.

As pharmaceutical companies work to develop potential vaccines and treatments for COVID-19, they are operating under extreme pressure—as well as the restrictions on movement and interaction that are affecting all of us.

On March 24, experts in finance, economics, and health from Global Network schools in seven countries gathered for an online conversation about the state of the COVID-19 pandemic, the economic fallout, and the path to recovery. 

In a Fortune commentary, Dr. Michael Apkon ’02, president and CEO of Tufts Medical Center, and Yale SOM’s Dr. Howard Forman and Jeffrey Sonnenfeld write that such an approach would be dangerous and ineffective.

Yale SOM’s Saed Alizamir, with Francis de Véricourt of ESMT and Shouqiang Wang of the University of Texas at Dallas, recently published a study that uses game theory to play out the tradeoffs that the WHO and other public agencies face as they try to give timely warnings while maintaining their credibility.

We talked with Dr. Suzanne Lagarde ’14, CEO of Fair Haven Community Health Care, about delivering healthcare to those who need it most.

Increased testing capacity is key to unlocking greater understanding of COVID-19 and learning how to slow its spread, according to Professor Howard Forman.

We asked Yale’s Howard P. Forman, a practicing radiologist and expert in healthcare management, what’s likely to happen with coronavirus in coming days and whether the U.S. healthcare system is prepared.